These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8109587)

  • 21. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial.
    Gregorio GV; Jara P; Hierro L; Diaz C; de la Vega A; Vegnente A; Iorio R; Bortolotti F; Crivellaro C; Zancan L; Daniels H; Portmann B; Mieli-Vergani G
    Hepatology; 1996 Apr; 23(4):700-7. PubMed ID: 8666320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon.
    Lisker-Melman M; Webb D; Di Bisceglie AM; Kassianides C; Martin P; Rustgi V; Waggoner JG; Park Y; Hoofnagle JH
    Ann Intern Med; 1989 Sep; 111(6):479-83. PubMed ID: 2774373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NIH consensus development statement on management of hepatitis B.
    Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
    NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-alpha.
    Teran JC; Mullen KD; Hoofnagle JH; McCullough AJ
    Hepatology; 1994 Apr; 19(4):849-56. PubMed ID: 8138256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B.
    Janssen HL; Berk L; Schalm SW; Heijtink RA; Hess G; Rossol S; Meyer zum Buschenfelde KH; Chamuleau RA; Jansen PL; Reesink HW
    Gut; 1992 Aug; 33(8):1094-8. PubMed ID: 1398234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term remission of chronic hepatitis B after alpha-interferon therapy.
    Korenman J; Baker B; Waggoner J; Everhart JE; Di Bisceglie AM; Hoofnagle JH
    Ann Intern Med; 1991 Apr; 114(8):629-34. PubMed ID: 2003708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection.
    Bozkaya H; Ayola B; Lok AS
    Hepatology; 1996 Jul; 24(1):32-7. PubMed ID: 8707278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin.
    Yalcin K; Degertekin H; Yildiz F; Kilinc N
    J Gastroenterol; 2003; 38(8):796-800. PubMed ID: 14505137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicentre randomized clinical trial of recombinant alpha-2a interferon therapy in patients with chronic hepatitis B.
    Rumi M; Romeo R; De Filippi F; Marcelli R; Del Ninno E; van Eyken P; Desmet V; Colombo M
    Ital J Gastroenterol; 1993 Apr; 25(3):117-20. PubMed ID: 8507888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels.
    Chen J; Xu CR; Xi M; Hu WW; Tang ZH; Zang GQ
    J Viral Hepat; 2017 Jul; 24(7):573-579. PubMed ID: 28107601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.
    Lampertico P; Del Ninno E; Manzin A; Donato MF; Rumi MG; Lunghi G; Morabito A; Clementi M; Colombo M
    Hepatology; 1997 Dec; 26(6):1621-5. PubMed ID: 9398007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
    Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
    [No Abstract]   [Full Text] [Related]  

  • 39. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).
    Carreño V; Marcellin P; Hadziyannis S; Salmerón J; Diago M; Kitis GE; Vafiadis I; Schalm SW; Zahm F; Manzarbeitia F; Jiménez FJ; Quiroga JA
    Hepatology; 1999 Jul; 30(1):277-82. PubMed ID: 10385667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
    Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
    Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.